MIT research shows positive results of skin patch for cancer treatment
By Nikita Chaurasia  Date: 2019-08-26

MIT research shows positive results of skin patch for cancer treatment
  • The skin patch designed, demonstrated positive results in an experiment on mice and human skin samples.
  • The MIT researchers designed the patch to fight melanoma cancer.

Researchers at the Massachusetts Institute of Technology reportedly announced successful results of a skin patch developed to offer cancer treatment in mice & human skin samples at the American Chemical Society conference in California, San Diego.

Apparently, the researchers at the MIT designed the patch to fight melanoma, a fatal but treatable skin cancer. For the uninitiated, Melanoma is subjected to be caused by an extreme exposure to UV rays from the sun or other sources. It has been claimed that the patch is less than a centimeter long and covered with a gluey film, which allows it to be applied and detached from the skin within a minute.

As per trusted reports, the researchers of the organization used the patch to deliver a toxin in healthy mice and later compared the immune response to other treatment methods used to vaccinate against the flu and measles. The results of the skin patch presented a robust antibody response along with a strong immune response in human skin.

The lead author of the study and HOD of Chemical Engineering, MIT, Dr. Paula Hammond reportedly stated that the organization’s recently designed patch technology can be used to offer vaccines to fight against various infectious diseases. Additionally, the researchers are pleased by the possibility of the patch to win against melanoma cancer.

The patch is embedded with microneedles, developed through a layer-by-layer coating process. This provides the advantage over syringes for its painless, easy to administer and reduced infection risk characteristics.

The researchers claimed that the patch treatment produced over 9 times the level of infection-fighting antibodies while comparing to the intramuscular injections. Additionally, it also produced over 160 times the level of antibodies compared to subcutaneous injections.

Speculation has it that the research was aided by the U.S. Department of Defense along with the Koch Institute for Integrative Cancer Research at MIT and Singapore-MIT Alliance for Research and Technology.

Source credit: https://www.cnbc.com/2019/08/25/new-skin-patch-to-deliver-cancer-medicine-shows-promise-in-mice-mit-scientists-say.html

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Fractyl raises series E funding of USD 55 million for diabetes cure
Fractyl raises series E funding of USD 55 million for diabetes cure
By Nikita Chaurasia

Fractyl Laboratories raised series E funding of USD 55 million to continue financing the pivotal clinical trial of its potential non-surgical, non-drug treatment for Type 2 diabetes. As per the trusted sources, the capital will be invested on mass-b...

Nokia Corp. partners with IISc to improve telecommunication solutions
Nokia Corp. partners with IISc to improve telecommunication solutions
By Nikita Chaurasia

Finnish multinational telecommunications giant Nokia Corporation has recently made it to the headlines after entering into a joint venture agreement with IISc (Indian Institute of Science) to launch the Nokia CoE (Centre of excellence) for Networked ...

Motorola acquires Pelco Inc. to expand its video security services
Motorola acquires Pelco Inc. to expand its video security services
By Nikita Chaurasia

Chicago-based telecommunication company, Motorola Solutions Inc., has made it to the headlines through its acquisition of Pelco Inc. from Transom Capital Group for $110 million dollars. For those uninitiated, Pelco Inc. is a security and surveillanc...

NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials
NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials
By Nikita Chaurasia

U.S.-based pharmaceutical company NeuroRx Inc., along with Relief Therapeutics Holding AG, a Swiss drug development company, have reportedly declared that aviptadil (RLF-100) clinical trials have showcased quick recuperation of respiratory failures a...

Boehringer Ingelheim acquires GST to expand stem cell capabilities
Boehringer Ingelheim acquires GST to expand stem cell capabilities
By Nikita Chaurasia

Boehringer Ingelheim, a leader in pharmaceutical products, has recently made it to the headlines by acquiring Belgium-based veterinary biotech firm, Global Stem cell Technology (GST). According to reliable sources, the collaboration with GST will al...